Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view.
Disertori M, Gulizia MM, Casolo G, Delise P, Di Lenarda A, Di Tano G, Lunati M, Mestroni L, Salerno-Uriarte J, Tavazzi L. Disertori M, et al. J Cardiovasc Med (Hagerstown). 2016 Apr;17(4):245-55. doi: 10.2459/JCM.0000000000000368. J Cardiovasc Med (Hagerstown). 2016. PMID: 26895401 Free PMC article. Review.
[Remarks on polyparametric assessment of sudden death risk for primary prevention ICD implantation in patients with left ventricular dysfunction of ischemic and non ischemic etiology. Italian Association of Hospital Cardiologists (ANMCO) Experts Position Paper].
Disertori M, Gulizia MM, Casolo G, Delise P, Di Lenarda A, Di Tano G, Lunati M, Mestroni L, Salerno-Uriarte JA, Tavazzi L. Disertori M, et al. G Ital Cardiol (Rome). 2015 Nov;16(11):651-66. doi: 10.1714/2066.22442. G Ital Cardiol (Rome). 2015. PMID: 26571481 Italian.
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G; GISSI-AF Investigators. Disertori M, et al. J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38. doi: 10.2459/01.JCM.0000199778.85343.08. J Cardiovasc Med (Hagerstown). 2006. PMID: 16645357 Clinical Trial.
Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA 3rd, Buja G, Thiene G. Corrado D, et al. Among authors: disertori m. Circulation. 2003 Dec 23;108(25):3084-91. doi: 10.1161/01.CIR.0000103130.33451.D2. Epub 2003 Nov 24. Circulation. 2003. PMID: 14638546 Clinical Trial.
Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry.
Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M, Padeletti L, Molon G, Botto G, De Santo T, Valsecchi S; InSync/InSync ICD Italian Registry Investigators. Boriani G, et al. Eur Heart J. 2009 Sep;30(18):2275-83. doi: 10.1093/eurheartj/ehp226. Epub 2009 Jun 10. Eur Heart J. 2009. PMID: 19515689 Free PMC article.
Myocardial fibrosis predicts ventricular tachyarrhythmias.
Disertori M, Masè M, Ravelli F. Disertori M, et al. Trends Cardiovasc Med. 2017 Jul;27(5):363-372. doi: 10.1016/j.tcm.2017.01.011. Epub 2017 Feb 2. Trends Cardiovasc Med. 2017. PMID: 28262437 Review.
175 results